Login / Signup

Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics.

Jessica Pougoue KetchemenHanan BabekerAnjong Florence TikumAnand Krishnan NambisanFabrice Ngoh NjotuEmmanuel NwangeleHumphrey Fonge
Published in: British journal of cancer (2023)
Using these biologics simultaneously as biparatopic theranostic agents has additive benefits.
Keyphrases
  • photodynamic therapy
  • fluorescence imaging
  • adverse drug
  • breast cancer risk
  • emergency department
  • young adults
  • iron oxide